Skip to main content
. 2020 Oct 27;20:100673. doi: 10.1016/j.conctc.2020.100673

Table 1.

Recommended 1st and 2nd line antiretroviral therapy (ART) regimens for children and youth in Kenya [33,34].

Age and weight Recommended 1st line ART at study start Updated 1st line ART during study implementation Recommended 2nd line ART
Birth-4 weeks AZT + 3 TC + RAL or NVP AZT + 3 TC + RAL or NVP ABC + 3 TC + LPV/r
>4 weeks and <3 years, <20 kg AZT (or ABC) + 3 TC + LPV/r ABC + 3 TC + LPV/r DRM testing-guided 2nd line
≥3 years and 20–35 kg ABC (or AZT) + 3 TC + EFV (or RAL) ABC (or AZT) + 3 TC + LPV/r ABC + 3 TC + DTG ABC (or AZT) + 3 TC + LPV/r DRM testing-guided 2nd line
≥15 years or >35 kg TDF (or ABC) + 3 TC + DTG (or EFV) TDF + 3 TC + DTG AZT (or TDF) + 3 TC + ATV/r

ART = antiretroviral therapy; AZT = zidovidine; 3 TC = lamivudine; RAL = raltegravir; NVP = nevirapine; ABC = abacavir; LPV/r = lopinavir/boosted ritonavir; EFV = efavirenz; TDF = tenofovir; DTG = dolutegravir; DRM = drug resistance mutation; ATV/r = atazanavir/boosted ritonavir.